Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

Open access
Willeit, Peter, Kaptoge, Stephen, Welsh, Paul, Butterworth, Adam S, Chowdhury, Rajiv, Spackman, Sarah A, Pennells, Lisa, Gao, Pei, Burgess, Stephen, Freitag, Daniel F, Sweeting, Michael, Wood, Angela M, Cook, Nancy R, Judd, Suzanne, Trompet, Stella, Nambi, Vijay, Olsen, Michael Hecht, Everett, Brendan M, Kee, Frank, Ärnlöv, Johan, Salomaa, Veikko, Levy, Daniel, Kauhanen, Jussi, Laukkanen, Jari A, Kavousi, Maryam, Ninomiya, Toshiharu, Casas, Juan-Pablo, Daniels, Lori B, Lind, Lars, Kistorp, Caroline N, Rosenberg, Jens, Mueller, Thomas, Rubattu, Speranza, Panagiotakos, Demosthenes B, Franco, Oscar H, de Lemos, James A, Luchner, Andreas, Kizer, Jorge R, Kiechl, Stefan, Salonen, Jukka T, Wannamethee, S Goya, de Boer, Rudolf A, Nordestgaard, Børge G, Andersson, Jonas, Jørgensen, Torben, Melander, Olle, Ballantyne, Christie M, DeFilippi, Christopher, Ridker, Paul M, Cushman, Mary, Rosamond, Wayne D, Thompson, Simon G, Gudnason, Vilmundur, Sattar, Naveed, Danesh, John, Di Angelantonio, Emanuele·2016·The Lancet Diabetes & Endocrinology

Abstract

BACKGROUND: Guidelines for primary prevention of cardiovascular diseases focus on prediction of coronary heart disease and stroke. We assessed whether or not measurement of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) concentration could enable a more integrated approach than at present by predicting heart failure and enhancing coronary heart disease and stroke risk assessment. METHODS: In this individual-participant-data meta-analysis, we generated and harmonised individual-participant data from relevant prospective studies via both de-novo NT-proBNP concentration measurement of stored samples and collection of data from studies identified through a systematic search of the literature (PubMed, Scientific Citation Index Expanded, and Embase) for articles published up to Sept 4, 2014, using search terms related to natriuretic peptide family members and the primary outcomes, with no language restrictions. We calculated risk ratios and measures of risk discrimination and reclassification across predicted 10 year risk categories (ie, <5%, 5% to <7·5%, and ≥7·5%), adding assessment of NT-proBNP concentration to that of conventional risk factors (ie, age, sex, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol concentrations). Primary outcomes were the combination of coronary heart disease and stroke, and the combination of coronary heart disease, stroke, and heart failure. FINDINGS: We recorded 5500 coronary heart disease, 4002 stroke, and 2212 heart failure outcomes among 95 617 participants without a history of cardiovascular disease in 40 prospective studies. Risk ratios (for a comparison of the top third vs bottom third of NT-proBNP concentrations, adjusted for conventional risk factors) were 1·76 (95% CI 1·56-1·98) for the combination of coronary heart disease and stroke and 2·00 (1·77-2·26) for the combination of coronary heart disease, stroke, and heart failure. Addition of information about NT-proBNP concentration to a model containing conventional risk factors was associated with a C-index increase of 0·012 (0·010-0·014) and a net reclassification improvement of 0·027 (0·019-0·036) for the combination of coronary heart disease and stroke and a C-index increase of 0·019 (0·016-0·022) and a net reclassification improvement of 0·028 (0·019-0·038) for the combination of coronary heart disease, stroke, and heart failure. INTERPRETATION: In people without baseline cardiovascular disease, NT-proBNP concentration assessment strongly predicted first-onset heart failure and augmented coronary heart disease and stroke prediction, suggesting that NT-proBNP concentration assessment could be used to integrate heart failure into cardiovascular disease primary prevention. FUNDING: British Heart Foundation, Austrian Science Fund, UK Medical Research Council, National Institute for Health Research, European Research Council, and European Commission Framework Programme 7.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(16)30196-6

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 223

Metadata

Authors
Willeit, P., Kaptoge, S., Welsh, P., Butterworth, A. S., Chowdhury, R., Spackman, S. A., Pennells, L., Gao, P., Burgess, S., Freitag, D. F., Sweeting, M., Wood, A. M., Cook, N. R., Judd, S., Trompet, S., Nambi, V., Olsen, M. H., Everett, B. M., Kee, F., Ärnlöv, J., Salomaa, V., Levy, D., Kauhanen, J., Laukkanen, J. A., Kavousi, M., Ninomiya, T., Casas, J.-P., Daniels, L. B., Lind, L., Kistorp, C. N., Rosenberg, J., Mueller, T., Rubattu, S., Panagiotakos, D. B., Franco, O. H., de Lemos, J. A., Luchner, A., Kizer, J. R., Kiechl, S., Salonen, J. T., Wannamethee, S. G., de Boer, R. A., Nordestgaard, B. G., Andersson, J., Jørgensen, T., Melander, O., Ballantyne, C. M., DeFilippi, C., Ridker, P. M., Cushman, M., Rosamond, W. D., Thompson, S. G., Gudnason, V., Sattar, N., Danesh, J., & Di Angelantonio, E.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2016-10
Volume
4
Issue
10
Pages
840-849
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2556674574
Cited by
223
References
13
FWCI
3.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. https://app.cochat.ai/papers/10.1016/s2213-8587(16)30196-6
The paper
Willeit, P., Kaptoge, S., Welsh, P., Butterworth, A. S., Chowdhury, R., Spackman, S. A., Pennells, L., Gao, P., Burgess, S., Freitag, D. F., Sweeting, M., Wood, A. M., Cook, N. R., Judd, S., Trompet, S., Nambi, V., Olsen, M. H., Everett, B. M., Kee, F., . . . Di Angelantonio, E. (2016). Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(16)30196-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.